Efficacy markers in depression.
Current antidepressant agents are similar in efficacy to the original drugs discovered in the 1950s. The development of new treatments for depression is, however, limited by the absence of validated human biomarker models to predict efficacy, clinical profile and dosing. Such models need to meet key...
Auteurs principaux: | Harmer, C, Cowen, P, Goodwin, G |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
2011
|
Documents similaires
-
Efficacy markers in depression
par: Harmer, C, et autres
Publié: (2011) -
Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms.
par: Hayward, G, et autres
Publié: (2005) -
Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms
par: Hayward, G, et autres
Publié: (2005) -
Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression.
par: Bhagwagar, Z, et autres
Publié: (2004) -
Elevated waking cortisol levels in neuroticism: A biological vulnerability factor for depressive disorders?
par: Portella, M, et autres
Publié: (2004)